Trials / Completed
CompletedNCT00694707
Safety and Efficacy of Cariprazine (RGH-188) in the Acute Exacerbation of Schizophrenia
Evaluation of the Safety and Efficacy of RGH-188 in the Acute Exacerbation of Schizophrenia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 732 (actual)
- Sponsor
- Forest Laboratories · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
This is a study to evaluate the safety, efficacy, and tolerability of cariprazine (RGH-188) relative to placebo in adult patients (18-60 years of age) with acute exacerbation of schizophrenia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Placebo was supplied in capsules. |
| DRUG | Cariprazine | Cariprazine was supplied in capsules |
| DRUG | Risperidone | Risperidone was supplied in capsules |
Timeline
- Start date
- 2008-06-30
- Primary completion
- 2009-08-31
- Completion
- 2009-08-31
- First posted
- 2008-06-10
- Last updated
- 2019-06-12
- Results posted
- 2019-06-12
Locations
65 sites across 5 countries: United States, India, Malaysia, Russia, Ukraine
Source: ClinicalTrials.gov record NCT00694707. Inclusion in this directory is not an endorsement.